pramipexole prami info and studies i found

[GOT FIGHT?]

Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.

Schilling JC, Adamus WS, Palluk R.

Human Pharmacology Centre, Boehringer Ingelheim KG, Germany.

The effects and tolerability of pramipexole, a new dopamine D2-receptor agonist, on prolactin, human growth hormone, thyrotropin, cortisol, and corticotropin levels were investigated in a randomized, double-blind, crossover study in 12 healthy volunteers. Single oral doses of 0.1, 0.2, and 0.3 mg pramipexole and placebo were studied over a period of 24 hours. Pramipexole decreased serum prolactin levels in a dose-dependent manner, with a maximum effect after 2 to 4 hours. Serum levels of human growth hormone were dose-dependently increased; however, this effect was only significant 2 hours after drug administration. Furthermore, a slight increase in serum cortisol levels and a slight decrease in serum thyrotropin levels was observed. Our findings show for the first time pharmacodynamic effects of pramipexole after single oral doses in healthy volunteers. The compound was well tolerated and showed an endocrine profile similar to other dopamine D2-agonists.

[GOT FIGHT?]

Munhoz RP, Fabiani G, Becker N, Teive HA.

Movement Disorders Unit, Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.

INTRODUCTION: Several recent reports have linked the use of dopamine agonists (DAs) to a variety of compulsive behaviors in patients with Parkinson's disease (PD). These inappropriate behaviors may include pathological gambling, compulsive shopping, and hypersexuality. AIM: To report the case of a patient with increased range of sexual behavior after use of pramipexole, a DA. METHODS: A 67-year-old man with a 7-year diagnosis of PD treated with levodopa and pramipexole presented with a dramatic change in sexual behavior after an increase in DA dose. RESULTS: The patient, who historically was a very shy and conservative person, started to present increased frequency of sexual intercourse with his wife, during which he began speaking obscenities with an extreme preference for anal intercourse, preferences never requested before. After pramipexole was withdrawn, complete remission was observed with return to his usual sexual behavior. CONCLUSIONS: Hypersexuality and paraphilias are complications not uncommonly found in patients with PD under dopaminergic treatment. Further studies are needed for the understanding of this complex complication, and particularly the most prevalent relationship between pathological hypersexuality and use of DAs.

[GOT FIGHT?]

In all clinical studies, dosage was initiated at a subtherapeutic level to avoid orthostatic hypotension and severe adverse effects. Pramipexole should be titrated gradually in all patients. The dosage should be increased to achieve maximal therapeutic effect, balanced against the principal adverse reactions of dyskinesia, nausea, dizziness and hallucinations.

Initial Treatment: Dosages should be increased gradually from a starting dose of 0.375 mg/day given in 3 divided doses and should not be increased more frequently than every 5 to 7 days. A suggested ascending dosage schedule that was used in clinical studies is shown in Table II.

The maximal recommended dose is 4.5 mg/day. Pramipexole is not recommended at the 6 mg/day dose since the incidence of some adverse reactions is higher.

Maintenance Treatment: Pramipexole was effective and well tolerated over a dosage range of 1.5 to 4.5 mg/day, administered in equally divided doses 3 times/day, as monotherapy or in combination with levodopa (approximately 800 mg/day). In a fixed-dose study in patients with early Parkinson's disease, pramipexole at doses of 3, 4.5 and 6 mg/day was not shown to provide any significant benefit beyond that achieved at a daily dose of 1.5 mg/day. For individual patients who have not achieved efficacy at 1.5 mg/day, higher doses can result in additional therapeutic benefit.

When pramipexole is used in combination with levodopa, a reduction of the levodopa dosage should be considered. In the controlled study in advanced Parkinson's disease, the dosage of levodopa was reduced by an average of 27% from baseline.

Patients with Renal Impairment: Since the clearance of pramipexole is reduced in patients with renal impairment (see Pharmacology, Pharmacokinetics), the following dosage recommendation should be considered.

Discontinuation of Treatment: It is recommended that pramipexole be discontinued over a period of 1 week. However, in some studies, abrupt discontinuation was uneventful.

[GOT FIGHT?]

Hope soem of this helps. I couldnt find a lot of info on it and seen a lot of questions related to what I posted on the boards. My rat is currently taking .75 mgs before bed and has expierienced major increase in libido and some pretty crazy and lifelike dreams. Waking up feeling rested and remembering an entire dream was a plus in his mind.

[gymnerd]

Prami is some crazy shit. I usually tolerate drugs well and do not get alot of sides but this stuff was brutal at only .5 mg ed have to slowwwwly ramp up on this stuff.

[Slide]

I second that, i puked and passed out after trying to start at 1mg

[AnimalJ]

**** prami lol. it made me feel horrible and SICK. Nausea, vomiting, upset stomach, fever, and tired tired tired.

[MBMETC]

Munhoz RP, Fabiani G, Becker N, Teive HA.

Movement Disorders Unit, Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.

INTRODUCTION: Several recent reports have linked the use of dopamine agonists (DAs) to a variety of compulsive behaviors in patients with Parkinson's disease (PD). These inappropriate behaviors may include pathological gambling, compulsive shopping, and hypersexuality. AIM: To report the case of a patient with increased range of sexual behavior after use of pramipexole, a DA. METHODS: A 67-year-old man with a 7-year diagnosis of PD treated with levodopa and pramipexole presented with a dramatic change in sexual behavior after an increase in DA dose. RESULTS: The patient, who historically was a very shy and conservative person, started to present increased frequency of sexual intercourse with his wife, during which he began speaking obscenities with an extreme preference for anal intercourse, preferences never requested before. After pramipexole was withdrawn, complete remission was observed with return to his usual sexual behavior. CONCLUSIONS: Hypersexuality and paraphilias are complications not uncommonly found in patients with PD under dopaminergic treatment. Further studies are needed for the understanding of this complex complication, and particularly the most prevalent relationship between pathological hypersexuality and use of DAs.

ha ha ha nice give it to me in the dumper, old perv...lol